Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate

Hosokawa, Toshihiko; Otani, Yoichi; Ogawa, Kenji; Kajiwara, Tetsuro

doi:10.1007/bf01211796

Cited by 3 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irsogladine, which has been clinically used as an anti-gastric ulcer agent in Japan, has been reported to have efficacy in metastatic [15] and inoperable gastric cancer [16] when combined with UFT (a mixture of tegafur and uracil in a molar ratio of 1:4). Experimentally, irsogladine has been shown to inhibit angiogenesis [10,11] and carcinogenesis [17,18].…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Breast Cancer Regrowth and Pulmonary Metastasis in Nude Mice by Anti-gastric Ulcer Agent, Irsogladine

Nozaki

Maeda²,

Tsuda³

et al. 2004

Breast Cancer Res Treat

View full text Add to dashboard Cite

Irsogladine is a commonly used anti-gastric ulcer agent in Japan, and recent in vivo studies have shown it to have anti-angiogenic properties. The exact role of irsogladine as an inhibitor of angiogenesis remains uncertain. In this study, we show that irsogladine inhibited breast cancer regrowth and pulmonary metastasis but had no anti-angiogenic function against HUVEC cells.Irsogladine failed to inhibit proliferation, tubular formation, and the uPA/MMP-1 mRNA expression of HUVEC cells. We also examined the effect of irsogladine in an orthotopic transplant model of human breast cancer metastasis in athymic mice. Human MDA-MB-435 cells were injected into the mammary fat pads. After nine weeks, the tumors were resected under general anesthesia. Irsogladine or vehicle was given p.o. daily thereafter. Daily administration of irsogladine at 120 mg/kg/day over a five-week period had no effect on the body weight of the mice. Tumor regrowth, average volume of pulmonary metastases, and the number of metastases were inhibited by 40, 48 and 64%, respectively. These results suggest that irsogladine may be useful in the breast cancer adjuvant setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of Breast Cancer Regrowth and Pulmonary Metastasis in Nude Mice by Anti-gastric Ulcer Agent, Irsogladine

Nozaki

Maeda²,

Tsuda³

et al. 2004

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Suppressing Effects of 6‐(2,5‐Dichlorophenyl)‐2,4‐diamino‐1,3,5‐triazine and Related Synthetic Compounds on Azoxymethane‐induced Aberrant Crypt Foci in Rat Colon

Hirose

Tanaka

Makita

et al. 1996

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

The modifying effects of dietary administration of 6‐(2,5‐dichlorophenyl)‐2,4‐diamino‐1,3,5‐triazine and 5 related compounds on the occurrence of azoxymethane (AOM)‐induced colonic aberrant crypt foci (ACF) were investigated in rats. Male F344 rats were given s.c. injections of AOM (15 mg/kg body weight) once a week for 3 weeks to induce ACF. They also received the diet containing 200 ppm test compound for 5 weeks, starting one week before the first dosing of AOM. At the termination of experiment, all of the compounds had caused a significant reduction in ACF frequency, which might be associated with suppression of the expression of proliferation biomarkers. The apoptotic index in the colonic mucosal epithelium of rats killed at 6 h after the first AOM exposure revealed no blocking activity of the compounds.

show abstract

Triazine Derivatives Inhibit Rat Hepatocarcinogenesis but Do Not Enhance Gap Junctional Intercellular Communication

Hori

Asamoto

Krutovskikh

et al. 1997

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

We report here novel candidate chemopreventive agents active against experimental hepatocarcino‐genesis. The triazine derivatives 6‐(2‐chlorophenyl)‐2,4‐diamino‐l,3,5‐triazine (2CPDAT), 6‐(3‐chlorophenyl)‐2,4‐diamino‐l,3,5‐triazine (3CPDAT), 6‐(4‐chlorophenyl)‐2,4‐diamino‐l,3,5‐triazine (4CPDAT), 6‐(4‐pyridyl)‐2,4‐diamino‐l,3,5‐triazine (PyDAT), and 6‐(pyridine JV‐oxid‐4‐yl)‐2,4‐diamino‐l,3,5‐triazine (PyNODAT), synthesized in our laboratory, in addition to 6‐(2,5‐dichloro‐phenyl)‐2,4‐diamino‐l,3,5‐triazme (DCPDAT), or irsogladine, which is a widely used anti‐ulcer drug, were investigated for potential chemopreventive effects in a rat liver medium‐term bioassay system. A significant inhibitory influence on enzyme‐altered liver foci was found for 2CPDAT, 3CPDAT, 4CPDAT, and PyNODAT, but not for DCPDAT or PyDAT, The involvement of gap jnnctional intercellular communication in the inhibition was studied, but no change in gap Junctional intercellular communication capacity in rat liver cells in vitro or in gap junction protein (connexin 32) expression in rat liver in vivo was noted. These results indicate that, although these irsogladine analogues exert inhibitory effects on rat liver carcinogenesis, their action is independent of modification of gap Junctional intercellular communication.

show abstract

Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate

Cited by 3 publications

References 1 publication

Inhibition of Breast Cancer Regrowth and Pulmonary Metastasis in Nude Mice by Anti-gastric Ulcer Agent, Irsogladine

Inhibition of Breast Cancer Regrowth and Pulmonary Metastasis in Nude Mice by Anti-gastric Ulcer Agent, Irsogladine

Suppressing Effects of 6‐(2,5‐Dichlorophenyl)‐2,4‐diamino‐1,3,5‐triazine and Related Synthetic Compounds on Azoxymethane‐induced Aberrant Crypt Foci in Rat Colon

Triazine Derivatives Inhibit Rat Hepatocarcinogenesis but Do Not Enhance Gap Junctional Intercellular Communication

Contact Info

Product

Resources

About